Generic drug
Lincomycin price, strengths & recalls
Lincomycin has no weekly pharmacy acquisition cost. 8 manufacturers make it. It is in shortage (being discontinued). It has 6 recalls on record, none ongoing. Its official label last changed on August 5, 2026.
Being discontinuedGenericLincomycin price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 300 mg/mL injection | Not priced this week | |||
Supply status: shortages & recalls
Shortages
- Lincocin, Injection, 10 mL multiple dose vial (NDC 0009-0107-04)Discontinuation of the manufacture of the drug
- Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)A business decision was made to discontinue manufacture of the drug.
- Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)A business decision was made to discontinue manufacture of the drug.
- Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Lincomycin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
Lincomycin Injection, USP Sterile Solution for Intramuscular and Intravenous Use
WARNING
Clostridioides difficileassociated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
C. difficile.
Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the
INDICATIONS AND USAGE
section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections.
C. diffficileproduces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of
C. difficilecause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibacterial use not directed against
C. difficilemay need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of
C. difficile, and surgical evaluation should be instituted as clinically indicated.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 5 approved generic applications on the market
Lincomycin questions
Is lincomycin in shortage?
Yes. 4 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has lincomycin been recalled?
6 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the lincomycin label last change?
The official label was last updated on August 5, 2026 (version 14). See what changed.
Talk about lincomycin
No comments yet. Questions, tips, what worked for you - start the conversation.